|本期目录/Table of Contents|

[1]戴济安,陶勇,刘开泰.手足口病流行病学及其疫苗的研究进展[J].慢性病学杂志,2018,(04):407-410.
点击复制

手足口病流行病学及其疫苗的研究进展(PDF)

《慢性病学杂志》[ISSN:1674-8166/CN:11-5900/R]

卷:
期数:
2018年04期
页码:
407-410
栏目:
综述
出版日期:
2018-04-28

文章信息/Info

Title:
-
作者:
戴济安1;  陶勇1;  刘开泰2
1. 中国疾病预防控制中心农村改水技术指导中心，北京102200 2. 中国疾病预防控制中心营养与健康所，北京100050
Author(s):
-
关键词:
手足口病; 肠道病毒71型; 灭活疫苗; 安全性：免疫原性; 保护效果
Keywords:
-
分类号:
R587.1
DOI:
-
摘要:
手足口病可由多种人肠道病毒引起，感染者表现为手、足、口的疱疹样症状，严重者可表现为神经系统症 状、呼吸系统症状以及全身性反应，甚至死亡。近些年来，世界上许多国家，尤其是西太平洋地区相继暴发手足 口疾病流行，成为一个世界性公共卫生问题。目前重症和死亡手足口病主要是由肠道病毒71 型（EV71） 引起， 我国已经研发出EV71 灭活疫苗并已上市，随着疫苗的使用和疾病流行特征的变化，EV71 所致手足口病正在逐 年减少。现将手足口病的流行病学和其疫苗相关研究作一综述。
Abstract:
-

参考文献/References:

[1] Ooi MH, Wong SC, Lewthwaite P, et al. Clinical features, diagnosis, and management of enterovirus 71 [J].Lancet Neurol, 2010,9(11):1097-1105.
[2] Yi EJ, Shin YJ, Kim JH, et al. Enterovirus 71 infection and vaccines [J]. Clin Exp Vaccine Res, 2017,6(1):4-14.
[3] Chumakov M, Voroshilova M, Shindarov L, et al. Entero- virus 71 isolated from cases of epidemic poliomyelitislike disease in Bulgaria [J]. Arch Virol, 1979,60:329-340.
[4] Liu SL, Pan H, Liu P, et al. Comparative epidemiology and virology of fatal and nonfatal cases of hand, foot and mouth disease in mainland China from 2008 to 2014 [J]. Rev Med Virol, 2015,25(2):115-128.
[5] 王丹.手足口病疫苗研发没有终结[N].健康报,2015-12-8(02).
[6] Solomon T, Lewthwaite P, Perera D, et al. Virology, epidemiology, pathogenesis, and control of enterovirus 71 [J]. Lancet Infect Dis, 2010,10(11):778-790.
[7] 李甜,邓莉.EV71 相关疫苗研究进展[J]. 北京医学,2015,37(10): 984-986.
[8] 安志杰,刘艳,廖巧红,等.肠道病毒71 型灭活疫苗使用技术指南 [J].中国疫苗和免疫,2016,22(4):458-464.
[9] National outline of epidemic situation of statutory infectious diseases. Available from:www.nhfpc.gov.cn/zhuzhan/yqxx/ lists.shtml.
[10] Shimizu H, Nakashima K. Surveillance of hand, foot, and mouth disease for a vaccine [J]. Lancet Infect Dis, 2014,14 (4):262-263.
[11] Xing W, Liao Q, Viboud C, et al. Hand, foot, and mouth disease in China, 2008- 12: an epidemiological study [J]. Lancet Infect Dis, 2014,14(4):308-318.
[12] 张永强,高燕琳,韦再华,等.2007-2015 年北京市手足口病的流 行病学特征分析[J].现代预防医学,2017,44(15):2689-2691.
[13] Yip CC, Lau SK, Woo PC, et al. Human enterovirus 71 epidemics: what's next [J]. Emerg Health Threats J, 2013 (6):19780.
[14] Chia MY, Chiang PS, Chung WY, et al. Epidemiology of enterovirus 71 infections in Taiwan [J]. Pediatr Neonatol, 2014,55(4):243-249.
[15] 罗凤基,杨晓明,王志军,等.疫苗学[M].6 版.北京:人民卫生出版 社,2017:2087-2088.
[16] 李甜,邓莉.EV71 相关疫苗研究进展[J]. 北京医学,2015,37(10): 984-986.
[17] Chong P, Hsieh SY, Liu CC, et al. Production of EV71 vaccine candidates [J]. Hum Vaccin Immunother, 2012,8 (12):1775-1783.
[18] 贾双双.EV71-CA16 联合灭活疫苗免疫保护效果研究[D].北京 协和医学院中国医学科学院,2016.
[19] Zhou Y, Li JX, Jin PF, et al. Enterovirus 71: a whole virion inactivated enterovirus 71 vaccine [J]. Expert Rev Vaccines, 2016,15(7):803-813.
[20] Zhu FC, Meng FY, Li JX, et al. Efficacy, safety, and immunology of an inactivated alum- adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double- blind, placebo- controlled, phase 3 trial [J]. Lancet, 2013,381(9882):2024-2032.
[21] Zhu F, Xu W, Xia J, et al. Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China [J]. N Engl J Med, 2014,370(8):818-828.
[22] Li R, Liu L, Mo Z, et al. An inactivated enterovirus 71 vaccine in healthy children [J]. N Engl J Med, 2014,370 (9):829-837.
[23] Mao Q, Cheng T, Zhu F, et al. The cross neutralizing activity of enterovirus 71 subgenotype c4 vaccines in heal - thy chineseinfants and children [J]. PLoS One, 2013,8(11): e79599.
[24] Bek EJ, Hussain KM, Phuektes P, et al. Formalin-inactivated vaccine provokes cross- protective immunity in a mouse model of human enterovirus 71 infection [J]. Vaccine, 2011,29(29-30):4829-4838.
[25] 白云骅,李淑萍,李丽,等.北京市朝阳区婴幼儿接种EV71疫苗的 安全性调查[J].中国热带医学,2017,17(12):1234-1236.
[26] 白云骅,李丽,张军楠,等.肠道病毒71 型灭活疫苗上市后安全性 主动监测[J].中国公共卫生,2017,33(7):1045-1047.
[27] Weng TY, Chen LC, Shyu HW, et al. Lactoferrin inhibits enterovirus 71 infection by binding to VP1 protein and host cells [J]. Antiviral Res, 2005,67(1):31-37.
[28] Matthews DA, Dragovich PS, Webber SE, et al. Structure- assisted design of mechanism-based irreversible inhibitors of human rhinovirus 3C protease with potent antiviral activity against multiple rhinovirus serotypes [J]. Proc Natl Acad Sci U S A, 1999,96(20):11000-11007.
[29] Arita M, Takebe Y, Wakita T, et al. A bifunctional antienterovirus compound that inhibits replication and the early stage of enterovirus 71 infection [J]. J Gen Virol, 2010,91 (Pt 11):2734-2744.
[30] Tsai FJ, Lin CW, Lai CC, et al. Kaempferol inhibits enterovirus 71 replication and internal ribosome entry site (IRES) activity through FUBP and HNRP proteins [J]. Food Chem, 2011,128(2):312-322.
[31] 陈梦娇.肠道病毒71型及甲乙型肝炎联合疫苗免疫原性的初步评 价[D].北京协和医学院中国医学科学院,2015.
[32] 叶静.灭活轮状病毒与灭活肠道病毒71型联合疫苗的制备及其免 疫效果评价[D].北京协和医学院中国医学科学院,2014.
[33] Mao QY, Wang Y, Bian L, et al. EV71 vaccine, a new tool to control outbreaks of hand, foot and mouth disease (HFMD) [J]. Expert Rev Vaccines, 2016,15(5):599-606.
[34] Liang ZL, Mao QY, Wang YP, et al. Progress on the research and development of inactivated EV71 whole- virus vaccines [J]. Hum Vaccin Immunother, 2013,9(8):1701- 1705.
[35] Lee MS, Tseng FC, Wang JR, et al. Challenges to licensure of enterovirus 71 vaccines [J]. PLoS Negl Trop Dis, 2012,6(8):e1737.

备注/Memo

备注/Memo:
作者简介：戴济安，在读研究生，研究方向：流行病学及 疫苗相关研究 通信作者：刘开泰，E-mail：kaitailiu@hotmail.com；陶勇， E-mail：taoyong@chinacdc.cn
更新日期/Last Update: 2018-04-28